Clinical DevelopmentALKS 2680 has shown a clear dose response in improving wakefulness with a favorable safety profile, positioning it as a strong candidate in the narcolepsy treatment landscape.
Product PerformanceLybalvi is on track to do close to $300M this year, surpassing the $400M peak sales expectation, highlighting the product's strong market acceptance and growth potential.
Strategic PartnershipsHarmony's decision to develop TPM-1116 underscores the importance of the OX2R agonist class, benefiting Alkermes by validating their approach to treating sleep/wake disorders.